Republic of Palau Comprehensive Cancer Control Plan

Objectives

Palau’s 2018–2023 Comprehensive Cancer Control Plan advances the vision “Cancer Free Me, Cancer Free Communities, Cancer Free Nation” by reducing cancer incidence, morbidity and mortality; improving survival and quality of life; and reducing cancer-related health disparities.[1][2][3]It operates as an annex to the Palau Non-Communicable Diseases Plan and covers prevention, screening, treatment, survivorship and quality of life, and health disparities.[1][2]

• Reduce cancer risks through tobacco control, healthier diets and weight, physical activity, safer sexual practices, vaccination and prevention or treatment of cancer-associated infections, including human papillomavirus and hepatitis B virus.[4][5][6]
• Prioritise high-burden cancers, including lung and bronchus, liver, prostate, oral cavity and pharynx, uterus, colorectal, breast, cervical, thyroid and stomach cancers.[7][8]
• Increase early detection through breast, cervical and colorectal screening, awareness of symptoms and bodily changes, and appropriate assessment of people at elevated risk.[4][9][10]
• Improve prompt, comprehensive and cost-effective treatment, aiming to increase the proportion of people receiving medically appropriate treatment and services within 90 days of diagnosis.[10][11]
• Strengthen survivorship, palliative and end-of-life support so that cancer survivors can live longer, healthy lives with physical, psychological and spiritual care.[11][12]
• Reduce disparities associated with age, sex, socioeconomic circumstances, geography, ability to pay, transport for off-island treatment and co-morbid conditions.[12][13]

Time-bound prevention objectives include strengthening immunisation advocacy, establishing consistent obesity messages, launching a youth smoking-prevention campaign, and introducing cancer prevention and control skills training for health professionals.[3][9]Quantified screening targets are to increase colorectal screening from 5% to 10% by 2023, cervical screening from 60% to 80% by 2022, and breast screening from 30% to 50% by 2022.[9][10]Health-disparity objectives seek to strengthen advocacy and education, increase screening among disparate groups, and expand access to support services by 2022.[13]

The plan responds to a substantial burden of late-stage disease: among 250 adults diagnosed with cancer between 2007 and 2015, 87% were diagnosed at stage 3 or higher and 65% died within five years.[4]It therefore combines prevention and earlier presentation with improved diagnosis, treatment, survivorship and palliative care.[8][14]

Implementation

Implementation uses a collaborative, whole-system model combining environmental approaches, community-clinical linkages and health-system change.[1][2]The Ministry of Health coordinates preventive and curative services, while the National Comprehensive Cancer Control Programme pools community resources and partnerships across the cancer continuum.[15][2]

• Coordinate implementation through the Ministry of Health Comprehensive Cancer Control Programme, the Palau Cancer Coalition, also known as Omellemel Ma Ulekerreuil a Bedenged, and the National Coordinating Mechanism for non-communicable diseases.[1][7]
• Engage public health services, community health centres, screening programmes, the Palau Cancer Registry, cancer survivors, caregivers, community organisations, government agencies, educational institutions, businesses, insurers and non-profit organisations.[2][16]
• Develop culturally appropriate education and communication materials, conduct outreach and advocacy, identify policy champions, and use age-appropriate media to promote prevention, screening and earlier care-seeking.[2][3][9]
• Assess service capacity, barriers, workforce skills, public knowledge and resource gaps before developing or expanding interventions.[3][9][10]
• Use telehealth, including Pacific Cancer ECHO, to support professional development in prevention, screening, treatment, survivorship and quality-of-life care.[9][10][11]

Prevention delivery includes human papillomavirus and hepatitis B vaccination, public education, breast and cervical screening, mammography, Pap smears and colorectal screening using faecal occult blood testing.[17]Pap smear samples are processed in the Philippines, while visual inspection with acetic acid and faecal immunochemical testing are reported as unavailable.[17]Clinical guidance covers cancer-specific examinations, laboratory testing, imaging, biopsy and treatment options appropriate to cancer site and stage.[5][6][18][19][20][21]

On-island treatment capacity is limited. Available surgeons and obstetrician-gynaecologists manage selected early cancers, while eligible patients may be referred to the Philippines, Taiwan or Hawaii for diagnosis or treatment.[8]Off-island referral funding is limited, requiring clinicians to judge which diagnostic and treatment services can safely be delivered locally.[8]Planned service improvements include comprehensive case management, a Ministry of Health cancer Service Center, a culturally appropriate directory of social support services, a multidisciplinary survivorship team, survivor guidelines, navigation processes and formal follow-up and treatment plans.[11][12]

The Palau Cancer Registry supports health-system priorities, screening-resource planning, outreach, policy action and community interventions.[14]Registry data are intended to monitor cancer patterns, identify opportunities for earlier detection, guide screening recommendations and assess awareness activities.[14]Monitoring also includes assessments of immunisation education, obesity messaging, youth smoking habits, screening capacity, screening-provider skills and workforce training needs.[3][9][10]The plan provides some outcome measures and deadlines, including screening targets and objectives due in 2020, 2021, 2022 and 2023, but does not specify a consolidated reporting schedule, detailed indicator framework, formal evaluation methodology or accountability timetable.[9][10][11][12]

Funding support is provided by the Centers for Disease Control and Prevention, while United States federal funding provides most dedicated health-service financing alongside local funds.[1][15][17]The plan identifies a need to secure fiscal and political support for a colorectal screening pilot and to furnish a dedicated cancer Service Center, but does not specify a monetary budget, costed activities, quantified funding gap or financing allocations.[10][11]

Monitoring & Evaluation

Monitoring combines plan review, time-bound implementation objectives, service and training assessments, screening measures, and cancer-registry data use; however, a consolidated indicator framework, reporting schedule and formal accountability process are not specified.[7][3][9][10][11][12]

• Review and update the plan as a dynamic annex to the Palau Non-Communicable Diseases Plan, with implementation supported by the Palau Comprehensive Cancer Control Program, the Palau Cancer Coalition and the National Coordinating Mechanism for non-communicable diseases.[7]
• Use the Palau Cancer Registry to collect and analyse cancer data, monitor cancer patterns and stage at diagnosis, identify opportunities for earlier detection, guide screening recommendations and evaluate awareness activities.[14]
• Use data and scientific research to prioritise interventions, drawing on expertise in evaluation, public health surveillance, programme development, health communication and clinical services.[2]
• Assess immunisation education needs, obesity communications, youth smoking behaviours, workforce training needs, screening capacity and barriers, and screening providers’ skills.[3][9][10]
• Evaluate youth smoking-prevention messages through survey assessment, and implement and evaluate the proposed colorectal screening programme.[9][10]
• Track screening targets to increase colorectal screening from 5% to 10% by 2023, cervical screening from 60% to 80% by 2022, and breast screening from 30% to 50% by 2022.[10]
• Assess gaps in case management, cancer Service Center provision and survivor follow-up, and evaluate survivorship guidelines and navigation processes after implementation.[11][12]
• Monitor time-bound treatment and survivorship ambitions, including medically appropriate treatment within 90 days of diagnosis and increased survival beyond five years after diagnosis.[11][12]
• Use available burden data to inform priorities: 250 adult cancers were recorded between 2007 and 2015, 65% of patients died within five years of diagnosis, and 87% were diagnosed at stage 3 or higher.[4]
• Recognise that the health-disparity objectives have a 2022 timeframe, but the available sections do not specify their indicators, monitoring methods, reporting requirements or responsible bodies for objectives on screening and support services.[13]
• Note that the source does not specify a comprehensive performance-reporting timetable, formal evaluation methodology, surveillance protocol or explicit accountability mechanism beyond implementation responsibilities and registry decision-support functions.[1][7][14][3][9][10][11][12]

Costing & Financing

Financing relies on external and public resources, including support from the Centers for Disease Control and Prevention and predominantly United States federal financing for dedicated health services, supplemented by local funds; the plan nevertheless identifies a need to secure additional resources.[1][15][17]

• Record per-capita health expenditure of 1,310 dollars in Palau, compared with more than 10,348 dollars in the United States.[15][17]
• Pool community resources through the National Comprehensive Cancer Control Program to reduce the cancer burden across risk reduction, early detection, treatment, survivorship and quality of life.[2]
• Secure fiscal and political support for the proposed colorectal cancer screening pilot.[10]
• Provide resources for dedicated hospital space, furnishing and augmented case-management services for a cancer Service Center, as well as training and Telehealth resources for cancer prevention, control and survivorship.[11][12]
• Recognise that limited off-island referral funding constrains diagnosis and treatment choices and requires clinicians to determine what can safely be delivered on island.[8]
• Note that no monetary cancer-plan budget, activity-level costing, resource-allocation framework, quantified funding gap, financing target or economic assumption is specified in the supplied sections.[1][7][8][4][5][6][18][19][20][21][10][11][12][13]